 SAN FRANCISCO, July 12, 2021 GLOBE NEWSWIRE -- FibroGen, Inc. NASDAQ: FGEN announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGens research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience. 